After commercial edibles became legally available in 2019, cannabis-related exposures were seen to be responsible for nearly 10 percent of all ED visits for poisonings in Ontario.
Doctors in Canada can now request psychedelic-assisted therapies for their patients through a new program, following an amendment to Health Canada’s Special Access Program (SAP).
The company behind the trial has expanded it to include three other behavioral addictions: binge eating disorder, compulsive sexual behavior and internet gaming disorder.
A group of researchers at the University of Mississippi School of Pharmacy have been awarded a $1.37 million grant to study whether cannabis compounds can treat HIV-related pain.
The researchers came to their conclusion after providing the drug to participants of a controlled trial of psilocybin-mediated therapy.
The recommendations have largely been welcomed by many in the UK’s CBD industry.
Participants in ayahuasca ceremonies report reductions in stress, anxiety, and depression whether they are given ayahuasca or not, a placebo-controlled study from researchers at Maastricht University has found.
Pfizer is set to acquire Arena Pharmaceuticals, a San Diego-based company currently developing a cannabinoid therapeutic called Olorinab.
The cannabis crop’s natural ability to accumulate heavy metal elements from the soil can pose a threat to the health of consumers, according to a new scientific review.
The new study from researchers at the University of Toronto suggests that cannabis users are more likely to sleep too little or too much than non-users.